Eli Lilly and Company, a pharmaceutical company, released its third quarter 2024 financial results, showing strong revenue growth driven by new product sales. Mounjaro and Zepbound, both diabetes and obesity medications, contributed significantly to revenue growth. The company also highlighted new drug approvals for Ebglyss (for atopic dermatitis) and Kisunla (for Alzheimer's disease). Future revenue guidance was updated to reflect continued investment in these products.